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Available online 9 August 2011Granisetron, a serotonin 5-HT3 receptor antagonist, widely used as an antiemetic drug
following chemotherapy, has been found to improve learning and memory. In this study,
effects of granisetron on spatial recognitionmemory and fearmemory and the involvement of
nitric oxide (NO) have been determined in a Y-maze and passive avoidance test. Granisetron
(3, 10mg/kg, intraperitoneally) was administered to scopolamine-induced memory-impaired
mice prior to acquisition, consolidation and retrieval phases, either in the presence or in the
absence of a non-specific NO synthase inhibitor, L-NAME (3, 10mg/kg, intraperitoneally); a
specific inducible NO synthase (iNOS) inhibitor, aminoguanidine (100mg/kg); and a NO
precursor, L-arginine (750mg/kg). It is demonstrated that granisetron improved memory
acquisition in a dose-dependent manner, but it was ineffective on consolidation and retrieval
phases of memory. The beneficial effect of granisetron (10 mg/kg) on memory acquisition
was significantly reversed by L-NAME (10 mg/kg) and aminoguanidine (100 mg/kg); however,
L-arginine (750 mg/kg) did not potentiate the effect of sub-effective dose of granisetron (3 mg/
kg) in memory acquisition phase. It is concluded that nitric oxide is probably involved in
improvement of memory acquisition by granisetron in both spatial recognition memory and
fear memory.
This article is part of a Special Issue entitled The Cognitive Neuroscience.
© 2011 Elsevier B.V. Open access under the Elsevier OA license.Keywords:
Granisetron
Spatial recognition memory
Fear memory
Nitric oxide
Mice1. Introduction
Granisetron which serves as a 5-HT3 antagonist of serotonin
receptors is of use in prevention of chemotherapy-induced
nausea and vomiting (Bermudez et al., 1988; Carmichael et al.,rmacology, School of Me
r (A.R. Dehpour).
to the study.
 the Elsevier OA license.1988; Gralla, 1993). On the other hand, 5-HT3 antagonists has
been found to obviously improve learning andmemory (Buhot
et al., 1999; Roman and Marchetti, 1998) and to antagonize the
effects of anticholinergic (Hodges et al., 1995) or age-induced
(Pitsikas and Borsini, 1996, 1997) memory loss; moreover, thedicine, Tehran University of Medical Sciences, P.O. Box 13145-784,
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the degree of cognitive impairment (Bowen et al., 1976;
Whitehouse, 1992) which is seen in the central nervous system
(CNS) of patientswith Alzheimer disease (Nakahiro et al., 1988)
has been proven. Following these studies, scientists have
shown that 5-HT3 receptors are involved directly and indirect-
ly in reduction of cholinergic release (Morales et al., 1996;
Ramírez et al., 1996) and 5-HT3 antagonists efficiently com-
pensate cholinergic dysfunction (Barnes et al., 1990; Buhot
et al., 1991; Chugh et al., 1991). It has been found that 5-HT3
agonist administration enhanced hippocampal cholinergic
function and this effect was eliminated by 5-HT3 receptor
antagonists (Meneses, 1999; Richter-Levin and Segal, 1996). On
the other hand, several behavioral studies have demonstrated
the interference of nitric oxide (NO) in particular forms of
memory formation and disturbance of learning by NO syn-
thase (NOS) inhibitors (Böhme et al., 1993; Chapman et al.,
1992; Meyer et al., 1998; Yamada et al., 1996). NO, a solvable,
short lived and freely dispersible gas, acts as an intracellular
retrogrademessenger in the brain (Garthwaite, 1991; Moncada
and Palmer, 1991) and participates in synaptic plasticity,
including long-term potentiation of the hippocampus (Haley
et al., 1992; O'Dell et al., 1991). NO apparently plays an im-
portant role in performance during the memory acquisi-
tion (Yamada et al., 1995); additionally, NO donors were able
to reverse NOS inhibitor-induced learning impairment
(Huang and Lee, 1995; Meyer et al., 1998). Presumably, the
nitric oxide (NO)-pathway is involved in serotonin-mediated
vasodilatation and also in serotonergic neurotransmission
(Bruning et al., 1993; Straub et al., 2007); in addition, NO
releases from cholinergic fibers and exists in the cholinergic
cells contacting the cortex (Mariño and Cudeiro, 2006). More-
over, it has been proposed that nitric oxide is involved in
the 5-HT3 receptors' proconvulsive action (Gholipour et al.,
2010), chloride secretory response to 5-HT3 activation in distal
colon (King et al., 2004) and also neurogenic relaxations of
guinea pig proximal colon (Sevcík et al., 1998); in addition, it
has been suggested that NO is involved in the pressor
response elicited by 5-HT3 stimulation in the nucleus tractus
solitarii (Sévoz-Couche et al., 2002) and 5-HT3 induced release
of substance P in rat spinal cord (Inoue et al., 1997) . However,
the role of NO pathway is still unclear in the granisetron
mechanism of action as a 5HT3 antagonist on learning
procedure.
Scopolamine-induced memory impairment is a generally
usedmodel to evaluate the effects of drugs on learning ability
and cognition status in experimental animals (Kopelman and
Corn, 1988; Stevens, 1981); scopolamine disarranges short-
term and working memory (Stevens, 1981); consequently,
different memory phases are affected (Abel and Lattal, 2001)
in Y-maze and passive avoidance task.
According to our knowledge, the present study is conducted
for the first time to investigate the granisetron mechanism
of action during acute administration on different phases of
memory (acquisition, consolidation and retrieval) in amnesic
mice; furthermore, we investigated the potential involvement
of NO pathway in positive effects of granisetron on memory
performance in memory impaired mice, using a NOS inhibitor,
L-NAME, a specific iNOS inhibitor, aminoguanidine and a
precursor of nitric oxide, L-arginine.2. Results
2.1. Y-maze
2.1.1. Effect of granisetron on acquisition of spatial
recognition memory
2.1.1.1. Effect of granisetron on memory acquisition. The
effect of granisetron (3 and 10 mg/kg) was evaluated in mice
with normal memory status. Total exploration time (factor
granisetron, F(1, 50)=0.802, P>0.05) and number (%) of arm
entries (factor granisetron, F(1, 50)=2.051, P>0.05) were not
affected by granisetron in saline-treated mice in comparison
with control group (data not shown); moreover, the entire
number of arm entries was similar in both experimental and
control groups, illustrating that general locomotor activity was
not influenced by granisetron (F(1, 15)=3.810, P>0.05; data not
shown).
2.1.1.2. Effect of granisetron on acquisition of memory induced
by scopolamine. The effect of granisetron on exploratory be-
havior was examined in scopolamine-induced memory im-
paired mice. As mentioned in our previous study (Allami et al.,
2011), scopolamine-treated mice were not able to discriminate
novel arm versus familiar arms in exploration time (F(2, 17)=
1.721, P>0.05; Fig. 1A) and number (%) of arm entries (F(2, 17)=
0.943, P>0.05; Fig. 1B) in acquisition trial. Memory impairment
induced by scopolamine has also been confirmed by significant
reduction in exploration time and number (%) of novel arm
entries in scopolamine-treated mice versus vehicle-treated
group, as shown in Fig. 1 (F(5, 48)=5.879, P<0.05; Fig. 1A; F(5, 48)=
6.074, P<0.001; Fig. 1B). Granisetron significantly improved the
compromised parameters in scopolamine-treated group, re-
spectively (F(11, 104)=6.789, P<0.001; Fig. 1A; F(11, 104)=3.029,
P<0.01; Fig. 1B) in a dose-dependent manner. In addition,
duration and number (%) of novel arm exploration was
significantly increased by granisetron (10 mg/kg) in comparison
with the start and other arms (F(2, 35)=30.770, P<0.001; Fig. 1A;
F(2, 35)=6.906, P<0.01; Fig. 1B). However, granisetron did not im-
prove exploration parameters in the novel arm at the dose of
3 mg/kg (F(2, 17)=1.270, P>0.05; Fig. 1A; F(2, 17)=2.288, P>0.05;
Fig. 1B).
Besides, the number of total arm entries was similar in all
experimental groups, demonstrating that general locomotor
activitywas affectedby granisetronneither in scopolamine-nor
in saline-treated groups (F(3, 34)=1.678, P>0.05; data not shown).
2.1.2. Effect of granisetron on consolidation and retrieval of
spatial recognition memory
2.1.2.1. Effect of granisetron on consolidation ofmemory impaired
by scopolamine. Fig. 2 demonstrates the effect of granisetron
on consolidation stage of spatial recognition memory. In
scopolamine-treated memory-impaired group, exploration
time (factor granisetron, F(11, 86)=2.119, P>0.05; Fig. 2A) and
number (%) of arm entries (factor granisetron, F(11, 86)=0.403,
P>0.05; Fig. 2B) did not show any significant change in
granisetron-treated group compared with vehicle-treated con-
trol mice.
Fig. 1 – Effect of granisetron on acquisition of spatial memory
in Y-maze task. Granisetron (3, 10 mg/kg), or vehicle (same
volume of saline) was administered 30 min prior training
sessions. Scopolamine (1 mg/kg) 30 min prior to training
session, impaired memory acquisition. Exploration time in
each arm (A) and the percentage of number of arm entries
(B) were measured. Values are expressed as the mean±SEM
from 6 to 8 animals and were analyzed using a multivariate
ANOVA for exploration time and the percentage of number of
arm entries, and one-way ANOVA for locomotor activity,
followed by Tukey's post test. +P<0.05 versus vehicle control
group; *P<0.05, **P<0.01, ***P<0.001 versus corresponding
novel group; #P<0.05, ##P<0.01 versus scopolamine-treated
group.
Fig. 2 – Effect of granisetron on spatial memory consolidation
in Y-maze task. Granisetron (3, 10 mg/kg) or saline was
administered immediately after training sessions. Memory
consolidation was impaired by scopolamine (1 mg/kg)
administered immediately after training session. Exploration
time in e-arm (A) and the percentage of number of arm
entries (B) were measured. Data represent means±SEM from
6 to 8 animals and were analyzed using a multivariate
ANOVA for exploration time and the percentage of number of
arm entries, and one-way ANOVA for locomotor activity,
followed by Tukey's post test. +P<0.05 versus vehicle control
group; **P<0.01, ***P<0.001 versus corresponding novel
group.
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scopolamine. The effect of granisetron on retrieval stage of
spatial recognitionmemory isdemonstrated inFig. 3. Exploration
time (factorgranisetron,F(8, 65)=0.605,P>0.05; Fig. 3A)andnumber
(%) of armentries (factor granisetron, F(8, 65)=1.404,P>0.05; Fig. 3B)
did not change significantly in granisetron-treated group com-
pared with vehicle-treated control in scopolamine-induced
memory-impaired mice.
2.1.3. Interaction of nitric oxide with the effect of granisetron
on acquisition of spatial recognition memory
2.1.3.1. Effects of L-NAME in antagonizing granisetron memory
improvement. According to our previous study (Allami et al.,
2011), administration of L-NAME (3 and 10 mg/kg) 30 min
before training session, had no effect on memory acquisition
and spontaneous locomotor activity either in saline- or in
scopolamine-treated groups; however, it nullified the benefi-cial effect of granisetron (10 mg/kg) on this memory stage, as
demonstrated in Fig. 4. L-NAME (10 mg/kg) significantly
declined novel arm exploration time and number (%) of
novel arm entries in granisetron-treated mice (F(8, 71)=5.694,
P<0.001; Fig. 4A; F(8, 71)=2.423, P<0.05; Fig. 4B). In addition, no
arm discrimination was seen in experimental group treated
with L-NAME (10 mg/kg) and granisetron showing a decrease
in general exploratory activity (F(2, 17)=1.011, P>0.05; Fig. 4A;
F(2, 17)=0.681, P>0.05; Fig. 4B). Moreover, locomotor activity
was not influenced by L-NAME in granisetron-treated mice
(F(2, 23)=1.796, P>0.05; data not shown).
2.1.3.2. Effects of aminoguanidine in antagonizing granisetron
memory improvement. Despite aminoguanidine (100 mg/kg)
had no effect on acquisition phase ofmemory by itself (Javadi-
Paydar et al., 2011), it nullified the positive effect of granisetron
(10 mg/kg) on this phase. Aminoguanidine, was administered
45 min before training session and significantly decreased
the novel arm exploration time and number (%) of novel arm
entries in granisetron treated mice (F(5, 53)=19.398, P<0.001;
Fig. 3 – Effect of granisetron on spatial memory retrieval in
Y-maze task. Granisetron (10mg/kg) or saline was adminis-
tered immediately after training sessions. Memory retrieval
was impaired by scopolamine (1 mg/kg) administered 30min
before the retention test. Exploration time in each arm (A) and
the percentage of number of arm entries (B) were measured.
Data represent means±SEM from 6 to 8 animals and were
analyzed using a multivariate ANOVA for exploration time
and the percentage of number of arm entries, and one-way
ANOVA for locomotor activity, followed by Tukey's post test.
+P<0.05, ++P<0.01 versus vehicle control group; *P<0.05,
**P<0.01, ***P<0.001 versus corresponding novel group.
Fig. 4 – Effect of L-NAME on granisetron memory enhance-
ment in spatial memory acquisition. Granisetron (10 mg/kg)
or vehicle (same volume of saline) was administered 30 min
before training sessions. Memory acquisition was impaired
by scopolamine (1 mg/kg), administered 30 min before
training session; L-NAME (3, 10 mg/kg) was administered
simultaneously with scopolamine. Exploration time in each
arm (A) and the percentage of number of arm entries (B) were
measured. Values are expressed as themean±SEM from 6 to
8 animals andwere analyzed using amultivariate ANOVA for
exploration time and the percentage of number of arm
entries and one-way ANOVA for locomotor activity, followed
by Tukey's post test. *P<0.05, **P<0.01, ***P<0.001 versus
corresponding novel group; &P<0.05, &&&P<0.001 versus
scopolamine-session treated group.
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was not influenced by aminoguanidine in granisetron treated
mice (F(1, 17)=1.007, P>0.05; data not shown).
2.1.3.3. Effects of L-arginine in agonizing granisetron memory
improvement. According to our previous study (Javadi-Paydar
et al., 2011), L-arginine (750mg/kg) administered 30min before
training session, did not change the exploration time and the
percentage of frequency of armentries inmemory acquisition
neither in saline-treated nor in scopolamine-treated groups.
Additionally, L-arginine did not potentiate the effect of
granisetron (3 mg/kg) on memory acquisition; as L-arginine
administration altered neither exploration time (F(5, 38)=
0.943, P>0.05; Fig. 6A) nor the percentage of frequency of
arm entries (F(5, 38)=1.604, P>0.05; Fig. 6B) in the novel arm in
granisetron-treated mice. Moreover, locomotor activity was
not changed by L-arginine (750 mg/kg) in granisetron-treated
(F(1, 12) =3.101, P>0.05; data not shown) compared with
vehicle-treated mice.2.2. Passive avoidance
2.2.1. Effect of granisetron on acquisition of long-term memory
2.2.1.1. Effect of granisetron on memory impairment induced by
scopolamine. In step-through latency (STL) using the passive
avoidance paradigm, granisetron administered 30 min prior to
training session, significantly increased latency time in mice
with impaired memory by scopolamine in a dose dependent
manner; while the same dose of drug did not show significant
difference in latency time inmice with normal memory status
(factor granisetron, F(2, 21)=2.705, P<0.01; Fig. 7).
Fig. 5 – Effect of aminoguanidine onmemory improvement by
granisetron in spatial memory acquisition. Granisetron
(10 mg/kg) or vehicle (same volume of saline) was
administered 45 min before training session. Memory
acquisition was impaired by scopolamine (1 mg/kg),
administered 30 min prior to training sessions;
aminoguanidine (100 mg/kg) was administered 45 min
before training session. Exploration time in each arm (A) and
the percentage of number of arm entries (B) were measured.
Values are expressed as the mean±SEM from 6 to 8 animals
and were analyzed using a multivariate ANOVA for
exploration time and the percentage of number of arm
entries and one-way ANOVA for locomotor activity, followed
by Tukey's post test. *P<0.05, **P<0.01, ***P<0.001 versus
corresponding novel group; ##P<0.01, ###P<0.001 versus
scopolamine-treated group.
Fig. 6 – Interaction of effect of L-arginine with granisetron in
spatial memory acquisition. Granisetron (3 mg/kg) or vehicle
(same volume of saline) was administered 30 min before
training sessions. Memory acquisition was impaired by
scopolamine (0.3 mg/kg), administered 30 min prior training
session; L-arginine (750 mg/kg) was administered
simultaneously with scopolamine. Exploration time in each
arm (A) and the percentage of number of arm entries (B) were
measured. Values are expressed as themean±SEM from 6 to
8 animals andwere analyzed using amultivariate ANOVA for
exploration time and the percentage of number of arm
entries and one-way ANOVA for locomotor activity, followed
by Tukey's post test.
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improvement. As shown in Fig. 8A, L-NAME administered
30min before training session, reduced latency time in passive
avoidance test, in a dose dependent manner (F(2, 24)=3.737,
P<0.05; Fig. 8A); moreover, L-NAME (10 mg/kg) had no effect on
latency time in acquisition phase by itself; however, it reversed
the beneficial effect of granisetron (10 mg/kg) on STL, as
demonstrated in Fig. 8B (F(1, 12)=11.623, P<0.01; Fig. 8B).
2.2.1.3. Effects of aminoguanidine in antagonizing granisetron
memory improvement. Despite aminoguanidine (100 mg/kg)did not change latency time in passive avoidance test (Fig. 9A),
it reversed the beneficial effect of granisetron (10 mg/kg) on
latency time in acquisition phase (Fig. 9B). Aminoguanidine,
administered 45 min before training session significantly
decreased the STL in granisetron-treated mice (F(1, 9)=14.318,
P<0.01; Fig. 9B).
2.2.1.4. Effects of L-arginine in agonizing granisetron memory
improvement. As shown in Fig. 10A, L-arginine (750 mg/kg)
had no effect on latency time in acquisition phase of fear
memory by itself; also, it did not potentiate the effect of sub-
effective dose of granisetron (3 mg/kg) in memory-impaired
mice (F(1, 12)=2.232, P>0.05; Fig. 10B).
Fig. 7 – Effect of granisetron on intact-memory and scopolamine-induced step-through latency impairment in
passive-avoidance task. Granisetron (3, 10 mg/kg) was administered 30 min before training sessions. The latency time to enter
the dark compartment was determined. Values are expressed as themean±SEM from 6 to 8 animals andwas analyzed using a
non-parametric ANOVA using a medians test. ***P<0.001 versus vehicle control group; #P<0.05 versus scopolamine-treated
group.
Fig. 8 – Effect of L-NAME on intact-memory (A) and memory
acquisition improvement by granisetron (B) in step-through
latency impairment in passive-avoidance task. Granisetron
(10 mg/kg) was administered 30min prior training sessions.
Memory acquisition was impaired by scopolamine (1 mg/kg)
administered 30min before training session; L-NAME
(3, 10 mg/kg) was administered simultaneously with
scopolamine. The latency time to enter the dark compartment
wasdetermined.Valuesare expressedas themean±SEMfrom
6 to 8 animals and was analyzed using a non-parametric
ANOVA using a medians test. *P<0.05 versus corresponding
novel group; #P<0.05 versus scopolamine-treated group;
&&P<0.01 versus scopolamine–granisetron-treated group.
Fig. 9 – Effect of aminoguanidine on intact-memory (A) and
aminoguanidine effect on memory improvement by
granisetron in step-through latency impairment (B) in
passive-avoidance task. Granisetron (10 mg/kg) or saline was
administered 30 min before training sessions. Memory
acquisition was impaired by scopolamine, (1 mg/kg)
administered 30min before training session; aminoguanidine
(100 mg/kg) was administered 45min prior training session.
The latency time to enter the dark compartment was
determined. Values are expressed as themean±SEM from6 to
8 animals and was analyzed using a non-parametric ANOVA
using a medians test. #P<0.05 versus scopolamine-treated
group; &&P<0.01 versus scopolamine–granisetron-treated
group.
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Fig. 10 – Effect of L-arginine on intact-memory (A) and its
interaction with granisetron (B) in acquisition of memory in
step-through latency. Granisetron (3 mg/kg) or saline was
administered 30 min before training session. Memory
acquisition was impaired by scopolamine (1 mg/kg),
administered 30 min before training session; L-arginine
(750 mg/kg) was administered simultaneously with
scopolamine. The latency time to enter the dark
compartment was determined. Values are expressed as the
mean±SEM from 6 to 8 animals and was analyzed using a
non-parametric ANOVA using a medians test.
67B R A I N R E S E A R C H 1 4 2 9 ( 2 0 1 2 ) 6 1 – 7 13. Discussion
The result of the present study determined for the first time
that NO pathway is involved in granisetron improving effect
on memory performance in scopolamine-induced memory-
impaired mice. Our findings revealed that administration of
granisetron improved both spatial recognitionmemory and fear
memory in scopolamine-induced memory-impaired mice, this
effect is not attributable to animal's locomotor activity and it is
reversed due to administration of nitric oxide synthase in-
hibitors; while determining the consolidation and retrieval
phase of memory, granisetron did not enhance the impaired-
memory performance in Y-maze task. Previous reports showed
that granisetron, a serotonin 5-HT3 antagonist, improved
acquisition, retention and retrieval of memory in passive
avoidance test (Chugh et al., 1991); however, others have
found that 5-HT3 receptorantagonistshavenoeffect on learning
in spatial discrimination (Buhot, 1997; Hodges et al., 1995). Some
evidences show that these antagonists attenuate age-associat-
ed memory impairment (Wolf, 2000) and even unimpaired-
memory (Chugh et al., 1991); In contrast, other reports suggest
the impairment of memory in water maze task by intrahippo-campal injectionofgranisetron (Naghdi andHarooni, 2005).This
discrepancy might be explained by the different cognitive task
tests used in their study and/or the different rout of drug
administration. It can also be attributed to the existence of
different 5-HT3 receptor splice variants on hippocampal CA1
that provide different sites of action for 5-HT3 receptor
antagonists. On the other hand, it has been found that 5-HT3
receptor agonists caused a substantial increase in cholinergic
release in cortical tissue and this effect was reversed by 5-HT3
receptor antagonists. This could be another explanation for this
discrepancy that the modulation of acetylcholine by 5-HT3
receptor antagonists cannot be ruled out as theirmechanismof
enhancement of memory and cognitive function (Chugh et al.,
1991). However, the exact mechanism of action involved in
effects of granisetron on memory performance has not been
evaluated extensively.
5-HT3 receptors, the targets of granisetron, are widely dis-
tributed in the rat brain and spinal cord, mainly in hippocam-
pus region (Mössner et al., 2004). These receptors, which are a
ligand-gated Na+ and K+ cation channel, play a prominent role
in the formation of learning and memory (Buhot et al., 1991;
Morales et al., 1996). 5-HT3 antagonists potently improve basal
performance in rodent and primate tests of cognition and
inhibit the impairments in performance caused by cholinergic
deficits (Barnes et al., 1990). In consistent with our results, it
has been shown that the 5-HT3 antagonists prevent scopol-
amine-induced memory deficits in various animal models
(Barnes et al., 1989; 1990; Chugh et al., 1991; Costall et al., 1978;
Fontana et al., 1995; Reznic and Staubli, 1997); however, con-
tradiction is also seen with other studies on animals (Naghdi
and Harooni, 2005) or humans (Benline and French, 1997).
As it is previously determined, NO is an important neuro-
transmitter involved in learning andmemory through synaptic
plasticity in various brain areas such as cerebellum and
hippocampus (Susswein et al., 2004). It seems that NO/cGMP
pathway plays a prominent role in processing within the
brain and it may be an important therapeutic target in pre-
venting and treating mild cognitive impairment (Austin et al.,
2010; Chu and Heistad, 2010). It has also been reported that
hippocampal NO facilitates the inhibitory avoidance learning
task in chicks and rats (Tan, 2007). Considering the role of NO
in learning and memory, it is shown that systemic administra-
tion of NOS inhibitors like L-NAME impairs spatial memory;
however, administration of low doses of L-NAME did not alter
the animal behavior in Y-maze task (Tanaka et al., 2009) and in
passive avoidance test (Yildirim and Marangoz, 2004); besides,
it has been reported that intraperitoneal administration of
another NOS inhibitor (Nω-nitro-L-arginine) impairs animal
performance in a radial-armmaze (Böhme et al., 1993).
The NO/cGMP pathway is presumed to be involved in
acetylcholine- and serotonin-mediated vasodilatation (Bruning
et al., 1993). Others have also suggested that the role of 5-HT3
receptor in neurogenic relaxations of guinea pig proximal
colon (Sevcík et al., 1998) and on human esophageal motility
(Willis et al., 1994) is at least partly mediated via release of NO
from nerve endings. The involvement of nitric oxide has also
beenproposedasoneof thepossiblepathways for theactivation
of soluble guanylate cyclase by serotonin in mouse neuroblas-
toma and rat glioma hybrid cells (Reiser, 1990). In addition, it
seems thatNO is involved inproconvulsiveactionofgranisetron
68 B R A I N R E S E A R C H 1 4 2 9 ( 2 0 1 2 ) 6 1 – 7 1(Gholipour et al., 2010). As a result, we have proposed in this
study, the involvement of nitric oxide pathway in granisetron
beneficial effect on memory performance. Our results support
the idea that the beneficial effect of granisetron on spatial
memory acquisition and fear memory which is reversed by
administration of both iNOS specific (aminoguanidine) andNOS
non-specific (L-NAME) inhibitorsmightbemediated through the
involvement of a NO-dependent pathway; although L-arginine,
a NO precursor, did not potentiate the effect of sub-effective
dose of granisetron.
In conclusion, our study demonstrates that granisetron
improved acquisition of scopolamine-induced short-term
memory and also fear memory impairment probably
through the involvement of nitrergic system in amnesic
mice. L-NAME, a non-selective NOS inhibitor, and amino-
guanidine, a selective iNOS inhibitor have been shown to
possess the ability to reverse the improving effect of
granisetron on acquisition of spatial memory and fear
memory, but L-arginine, a NO precursor do not potentiate
the effect of granisetron on acquisition stage. Our data, thus,
reinforce the idea that granisetron can be used as an adjunct
therapy in treatment of memory impairment, though further
clinical investigation are needed to assess its therapeutic
potential.4. Experimental procedures
4.1. Housing and handling of animals
The animals were handled according to the criteria outlined in
the Guide for the Care and Use of Laboratory Animals (NIH US
publication 86–23 revised 1985). NMRI male mice (Tehran
University of Medical Science, Tehran, Iran), 6–8 weeks of age,
were kept in a controlled environment (23±2 °C, 50±5%
humidity) under a 12 h light/dark cycle (light on 08.00–20.00)
and had free access to standard pellet chow and tap water
throughout the study. Each mouse was used once and each
treatment group comprised of 6–12 animals.
4.2. Chemicals and drugs
The L-NAME, scopolamine and aminoguanidine used in this
study were purchased from Sigma (St. Louis, USA), L-arginine
and granisetron were respectively purchased from Merck
(Darmstadt,Germany) andAburaihanPharmaceutical Company
(Tehran, Iran). All drugs were freshly diluted in physiological
saline and administrated intraperitoneally.
4.3. Y-maze task
The Y-maze is a simple two-trial recognition test for
evaluating spatial recognition memory. It is based on the
innate tendency of rodents to explore novel environments
(Allami et al. 2011; Dellu et al., 1992). It consists of three
horizontal arms (40 cm long, 3 cm wide walls and 12 cm
high) symmetrically disposed at 120° to each other. Each arm
had different clues for distinction from each other. The Y-
maze test comprised two trials separated by a 1 h inter-trialinterval. In the first trial (training), which lasted 10 min, each
mouse was placed at the end of the start arm and was
allowed to explore only two arms (including the start arm),
with the third arm (novel arm) being blocked. After 1 h, in the
second trial (retention), mouse was placed back in the maze,
at the same start arm with free access to all three arms,
being allowed to move freely during an 8 min period. The
number of arm entries and exploration time in each arm
were recorded manually using a stopwatch for each mouse
over an 8 min period. The total number of arm entries was
measured as an index of locomotor activity to rule out the
interference of changes in motility with the parameters of
learning and memory. To avoid the presence of olfactory
trials, maze arms were thoroughly cleaned between tests.
Recognition of the novel arm from the other two familiar
arms is considered as a memory improvement effect. Mice
which distinguish the unfamiliar arm show exploratory
behavior, so they spend more time and enter more frequent-
ly to the novel arm in comparison with the other familiar
ones.
4.4. Passive avoidance task
A step-through passive avoidance task was used to evaluate
the effect of granisetron on long-term memory (Kim et al.,
2008). Passive avoidance apparatus was consisted of a two
identical compartments (20×20×20 cm), illuminated and
non-illuminated boxes (Borj Sanat Company, Tehran, Iran),
separated by a guillotine door. The illuminated compart-
ment contained a 40 W bulb, and the floor of non-illuminat-
ed compartment was composed of 2 mm stainless steel rods
spaced 1 cm apart. During the training trial, each mouse was
placed in the lighted compartment, and when the mouse
entered the dark compartment the door closed and the
mouse received an inescapable electric shock (0.5 mA, 1 s).
The test trial was done 24 h after the training trial; in this
step, the mouse was again placed in the lighted compart-
ment and the latency time to enter the dark compartment
was measured. If the mouse did not enter the dark chamber
within the cut-off time (300 s), it was assigned a latency
value of 300 s.
4.5. Experimental design
4.5.1. Y-maze task
In all experimental groups, memory impairment was
induced by scopolamine (1 mg/kg) prior to each experimental
trial. Granisetron dose and the optimum time interval of
granisetron administration was determined according to our
pilot study. Corresponding vehicle controls were used in all
experiments.
4.5.1.1. Acquisition trial. Mice were administered granise-
tron (3 and 10 mg/kg) and scopolamine (1 mg/kg) 30 min
before training trials. Retention was performed according to
the following schema in the presence and absence of
scopolamine.
In two other sets of experiments, L-NAME (5, 10mg/kg)
(Allami et al., 2011) or L-arginine (750mg/kg) (Javadi-Paydar
et al., 2011) were administered 30min before training sessions;
in the third set of experiment aminoguanidine (100mg/kg)
69B R A I N R E S E A R C H 1 4 2 9 ( 2 0 1 2 ) 6 1 – 7 1(Javadi-Paydar et al., 2011) was administered 45 min before training session. Granisetron and scopolamine were administered as
same as described above.
4.5.1.2. Consolidation trial. Mice were administered granisetron (3 and 10 mg/kg) and scopolamine immediately after training
trials. Retention was performed according to the following schema in the presence and absence of scopolamine.
4.5.1.3. Retrieval trial. According to the following schema, granisetron (3 and 10 mg/kg) and scopolamine were respectively
administered immediately after training trial and in 30 min before retention test. The retention test was performed in an hour in
the presence and absence of scopolamine.
4.5.2. Passive avoidance
Memory impairmentwas inducedby scopolamine (1 mg/kg), 30 minbefore the training trial. In experimental group, granisetron
(3 and 10 mg/kg) was administered 30 min prior to training trial. Control animals were administered corresponding vehicle.
4.5.2.1. Acquisition trial. Mice were administered granisetron (3 and 10 mg/kg) and scopolamine 30 min before training trials.
Retention was performed according to the following schema in the presence and absence of scopolamine.
In two other sets of experiments, L-NAME (5, 10 mg/kg) (Allami et al., 2011) or L-Arginine (750 mg/kg) (Javadi-Paydar et al., 2011)
were administered 30 min before training session; in the third set of experiment aminoguanidine (100 mg/kg) (Javadi-Paydar et al.,
2011) was administered 45 min before training session. Granisetron and scopolamine were administered as same as described
above.
4.6. Statistical analysisThe results of each experimentwere expressed as: In Y-maze: 1) exploration time (seconds) for each armvisits; 2) percentage of
number of arm entries during an 8 min session; 3) total number of arm entries reflected as locomotor activity index. In passive
avoidance test, the latency time (seconds) to enter the dark compartment was measured in both acquisition and retention trials.
Data were expressed as mean±SEM and analyzed using SPSS statistical software package. Differences among treatment groups
were considered as between-group factor, whereas differences in arm entries and exploration time for each special treatment
were considered as within-group factor. Each of between group differences was assessed with multivariate analysis of variance
70 B R A I N R E S E A R C H 1 4 2 9 ( 2 0 1 2 ) 6 1 – 7 1(ANOVA) and Tukey's post test. One-way ANOVA was used to
determine the within-group differences in locomotors activity
and P<0.05 was considered statistically significant in all
experiments.
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